Instrument Inactif

Communiqués InDex Pharmaceuticals Holding AB (publ) Nasdaq Stockholm

Actions

SE0008966295

Produits pharmaceutiques

Communiqués

19/08	Flerie Invest : portfolio company Xspray Pharma receives CRL from FDA for Dasynoc®	PU
06/08	Bulletin from the Extraordinary General Meeting of Flerie AB (publ) on 6 August 2026 at 11:00 CEST (press release bulletin from the extraordinary general meeting of flerie ab publ on 6 august 2026 at 260806)	PU
04/08	Flerie Invest : NET ASSET VALUE - 31 July 2026	PU
09/07	Flerie Invest : AB (publ) Interim Report January - June 2026	PU
08/07	Flerie Invest : Notice of extraordinary general meeting of Flerie AB (publ) (press release notice of extraordinary general meeting of flerie ab publ 260708)	PU
02/07	Flerie Invest : NET ASSET VALUE - 30 June 2026	PU
26/06	Flerie Invest : portfolio company Bonsai Biotherapeutics receives full approval of clinical trial application for TOL2 in myasthenia gravis	PU
15/06	Bulletin from the extraordinary general meeting of Flerie AB (publ) on 15 June 2026 at 10:00 CEST	PU
29/05	Flerie Invest : Change in the total number of shares and votes in Flerie AB (publ)	PU
30/04	Flerie Invest : Change in the total number of shares and votes in Flerie AB (publ)	PU
15/04	Flerie Invest : Interim report Q1 2026 Presentation	PU
15/04	Flerie Invest : Interim report Q1 2026 Report	PU
05/03	Flerie Invest : Annual Report 2025 Report	PU
24/02	Flerie Invest : Notice to attend the Annual General Meeting of Flerie AB (publ)	PU
24/02	Flerie Invest : Board of Directors decides on a directed new share issue of SEK 76 million and proposes a bonus issue and termination of the share redemption programme after this year's redemption period	PU
21/01	Flerie Invest : Year-end Report 2025 Report	PU
03/12	Flerie Invest : NET ASSET VALUE - 30 November 2025	PU
02/12	Flerie Invest : and other major shareholders increase their ownership in Prokarium through an internal financing that reduces the reported net asset value	PU
26/11	Flerie Invest : Notice of extraordinary general meeting of Flerie AB (publ) (press release notice of extraordinary general meeting of flerie ab publ 251126)	PU
14/11	Flerie Invest : portfolio company Egetis Therapeutics ready for NDA after positive results from the ReTRIACt study with Emcitate®	PU
04/11	Flerie Invest : portfolio company Empros Pharma reports study results positioning EMP16 as a promising oral weight-loss maintenance therapy	PU
04/11	Flerie Invest : NET ASSET VALUE - 31 October 2025	PU
22/10/25	Flerie Invest : AB (publ) Interim Report January - September 2025	PU
15/10/25	Flerie Invest : Invitation to presentation of Flerie's Q3 2025 interim report	PU
08/10/25	Flerie Invest : portfolio company Xspray Pharma provides update on FDA process for Dasynoc®; observations at contract manufacturer delay approval	PU